Close

News

Canagliflozin ( Antidiabetic agent) wins The Technology Award Grand Prize from the Japan Chemical Industry Association (JCIA)

Mitsubishi Tanabe Pharma Corporation MTPC announced that Canagliflozin received the Technology Award Grand Prize at the 50th JCIA Awards. In the Awards, MTPC was highly recognized at the points success of the discovery of the excellent...

Internationalisation and regulatory reform driving growth and investment at CPhI China

CPhI & P-MEC China (#CPhIChina) – organized by UBM and UBM SINEXPO – takes place at the Shanghai New International Expo Center (SNIEC) on 20-22nd June 2018. Asia’s largest pharmaceutical event returns with recent regulatory reforms...

TraceLink Adds Industry Visionaries to Discuss Machine Learning, Artificial Intelligence, Big Data and Patient Engagement at FutureLink Munich

TraceLink Inc., the World's Largest Track and Trace Network for connecting the life sciences supply chain and providing real-time information sharing for better patient outcomes, announced the latest keynote speakers for its upcoming FutureLink Munich conference to be held...

Oxford Genetics announces new online customer portal for custom research services

Oxford Genetics, a leader in innovative synthetic biology-based technologies for biologics discovery, development and delivery, announced the launch of a new online customer portal designed to enable customers to better monitor project progress and track communications. ...

Boehringer Ingelheim R&D pushes to transcend disease boundaries

Family-owned pharmaceutical company Boehringer Ingelheim presented its latest pipeline updates at a Research & Development press conference entitled ‘Transcending Disease Boundaries’, at its global headquarters in Ingelheim, Germany. The company’s R&D strategy and current pipeline has...

Tjoapack invests in blistering capabilities

Global contract packaging organisation (CPO), Tjoapack has invested in its blistering capacity, adding a new line that will be equipped with late-stage customisation printing capabilities. Expected to be operational by the end of Q3 2018, the...

CEVEC and CSL Limited sign exclusive license agreement for production of recombinant C1 Esterase Inhibitor using CEVEC’s proprietary CAP(R)Go technology

CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, and global biotechnology leader CSL Limited announced an exclusive licensing agreement for the development, manufacture and commercialization of recombinant C1 Esterase Inhibitor...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »